TransCon CNP for Achondroplasia

(AttaCH Trial)

Recruiting at 14 trial locations

Age: < 18

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2 & 3

Waitlist Available

Sponsor: Ascendis Pharma Growth Disorders A/S

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial uses TransCon CNP to help children and adolescents with achondroplasia grow their bones properly. It is for those who have already been part of a previous trial. The treatment continues for an extended period.

Research Team

Vibeke Breinholt

Principal Investigator

Ascendis Pharma

Eligibility Criteria

This trial is for children and adolescents with achondroplasia who have already been part of a previous TransCon CNP study. They must be able to receive weekly injections, have parental consent, and meet safety criteria from the prior trial. Those unable to complete the study or at risk due to other conditions are excluded.

Inclusion Criteria

My guardian can give me weekly shots and follow the study rules.

I have achondroplasia and finished a trial with TransCon CNP.

My guardian has signed the consent form, and I will too when I'm of age.

Exclusion Criteria

I have taken prescription or investigational drugs other than TransCon CNP.

I am not allergic to the trial drug or its components.

I am not using effective birth control and am able to have children.

Treatment Details

Interventions

• TransCon CNP (Other)

Trial Overview The long-term safety, tolerability, and effectiveness of TransCon CNP given once a week are being tested in young patients with achondroplasia until they reach skeletal maturity (16 years for females, 18 years for males), confirmed by radiographic imaging.

Participant Groups

Group I: TransCon CNP 100 mcg Experimental Treatment 1 Intervention

TransCon CNP 100 mcg delivered once weekly by subcutaneous injection

Who Is Running the Clinical Trial?

Ascendis Pharma Growth Disorders A/S

Lead Sponsor

Trials

4

Recruited

320+